Antiviral Therapy

Papers
(The median citation count of Antiviral Therapy is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-1910
JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in p8
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B6
Case study of hepatitis C virus control in Egypt: impact of access program6
Tenofovir alafenamide fumarate6
The curing regimens of HCV: A SWOT analysis5
Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults5
Impact of new cyclooxygenase 2 inhibitors on human cytomegalovirus replication in vitro4
Antiretroviral therapy achieved metabolic complete remission of hepatic AIDS related Epstein-Barr virus-associated smooth muscle tumor4
Higher risk of mortality in HIV-HBV co-infected patients from sub-Saharan Africa is observed at lower CD4+ cell counts4
The transformation of HIV therapy: One pill once a day4
The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir4
Efficacy of second-line dolutegravir plus 2 nucleoside reverse transcriptase inhibitors by baseline nucleoside reverse transcriptase inhibitor resistance and nucleoside reverse transcriptase inhibitor4
Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase in silico approach4
Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey3
Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)–infected patients3
HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective3
Abstracts3
Letermovir use to treat complex cytomegalovirus reactivations in two heart transplant recipients3
Adefovir for lamivudine-resistant hepatitis B3
Herpes simplex virus reactivation in patients with COVID-19 and acute respiratory distress syndrome: a prospective cohort study3
Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study3
Polaris Observatory—supporting informed decision-making at the national, regional, and global levels to eliminate viral hepatitis3
Hepatitis C virus/Hepatitis B virus coinfection: Current prospectives3
Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: A scoping review3
Case report and literature review: A hiccup patient developed encephalitis and duodenal perforation2
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants2
Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study2
Discovery and development of oseltamivir at Gilead Sciences2
The making of the one pill—Developing single tablet regimens for HIV and for HCV2
Commentary: Development of Therapeutics for Congenital Cytomegalovirus Infection2
Understanding the effect of direct-acting antiviral therapy on weight in patients with chronic hepatitis C2
Fanconi syndrome, diabetes insipidus, and acute kidney injury due to tenofovir disoproxil fumarate: A case report2
Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts2
The role of tenofovir disoproxil fumarate for preventing vertical transmission of hepatitis B2
Socioeconomic status largely explains integrase inhibitors-related body composition differences in chronically infected men living with HIV2
Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting2
Real-life findings on the impact of the COVID-19 pandemic on HIV care2
Resistance levels to non-nucleoside reverse transcriptase inhibitors among pregnant women with recent HIV infection in Malawi2
An unexpected adverse effect: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide–induced cholestasis2
Pharmacokinetic interaction between raltegravir and rifampicin in an infant with HIV exposed to active TB: a case report2
Virus reactivation in a non-cirrhotic HBV patient requiring liver transplantation after cessation of nucleoside analogue therapy2
Antiviral effect of Artemisia aucheri aqueous extract on UL46 and US6 genes of HSV-12
Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers2
Providing access to high-quality, low-cost medicines across low and middle-income countries (LMICs), working with governments and generic manufacturers around the globe - A business case2
0.01692008972168